Apollo has been developed to fund a wide range of biomedical projects across a number of therapeutic areas. While the fund is focussed on therapeutics, or platform technologies which may aid the development and identification of therapeutics, there will be no therapeutic area bias, and any modality may be considered (e.g. small molecules, peptides, proteins, antibodies and gene/cell therapies). To provide some guidance, Apollo has initially identified a list of areas of interest, though it is not limited to providing funding only to these:

Technical criteria

  • Addresses unmet medical need
  • Target validation: evidence relating target to disease; independent verification, on-target liability, novelty
  • Molecular and clinical tractability
  • Screening: either phenotypic with deconvolution strategy or target/pathway identified
  • Status of assays and models for project: Robustness, access to reagents, availability, throughput, translatable relevance
  • Hit/lead properties (if available) activity, selectivity, physicochemical properties

Therapeutic areas of interest

These areas are not fixed, but preference will be given to applications falling within these specified areas. Please discuss your options with your local Apollo Imperial Management group representative (see contact details).


  • COPD
  • Asthma
  • Idiopathic pulmonary fibrosis
  • Acute lung injury
  • Cystic fibrosis
  • Idiopathic chronic cough


  • Inflammatory bowel disease
  • Rheumatoid Arthritis
  • SLE
  • OA
  • Transplantation
  • Niche inflammatory diseases
  • Psoriasis


  • Lung cancer including EGFR signalling pathway and agents addressing resistance to SOC
  • Breast cancer
  • Ovarian cancer
  • Urological cancers including prostate cancer, high risk or resistant patients
  • GI tract – Gastric and Liver, K-Ras mutant CRC
  • Haematological Cancers including AML, MM, MDS, NHL, CLL, DLBCL, Monoclonal gammopathy of undetermined significance (MGUS), in general agents addressing the B cell Receptor Signalling Pathway
  • Immuno-oncology approaches, epigenetic approaches and DNA repair

Metabolic and Cardiovascular

  • Obesity
  • Diabetes and Diabetic complications including nephropathy
  • Heart failure (systolic and diastolic) including congestive heart failure, calcium channel modulation, agents addressing mitochondrial dysfunction and novel anti fibrotic mechanisms and cardiac repair and regeneration, dyslepidemia
  • Muscle building and improved function in sarcopenia and cachexia

Infectious diseases

  • Anti-virals including hepatitis and respiratory viruses
  • Anti-bacterials
  • Vaccines


  • Neurodegeneration and Neuroinflammation including Alzheimers (e.g. alpha-synuclein antagonists, ApoE modulators, Gamma secretase modulators, Monoacylglycerol lipase inhibitors)
  • Mood disorders including Depression and Bipolar Disorders
  • Rare diseases (e.g. Metabolic, Imunno-inflammation, CNS, Muscle Disorders, Rare Malignancies and Haematology